Pedro Monteiro

Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)

L Rydén, Eberhard Standl, M. Bartnik et al. · European Heart Journal · 2006 · 1.7K citations · Full text

Medicine, Cardiology, Endocrinology +17

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Kausik K Ray, Helen M Colhoun, Michael Szarek et al. · The Lancet Diabetes & Endocrinology · 2019 · 328 citations · Full text

Medicine, Cardiology, Internal Medicine +15

Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer

Nelma Pértega‐Gomes, José R. Vizcaíno, Vera Miranda‐Gonçalves et al. · BMC Cancer · 2011 · 175 citations · Full text

Medicine, Molecular Biology, Oncology +13

Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME® trial

Pedro Monteiro, Richard M. Bergenstal, Elvira Toural et al. · Age and Ageing · 2019 · 132 citations · Full text

Pharmacy, Geriatric Medicine, Pharmacotherapy +15

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Emil Hagström, Philippe Gabríel Steg, Michael Szarek et al. · Circulation · 2022 · 122 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17